Bristol-Myers Squibb Co
BMY
Company Profile
Business description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Contact
Route 206 and Province Line Road
Princeton
New JerseyNJ08543
USAT: +1 609 252-4621
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
34,100
Bristol-Myers Squibb Co News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks
5 undervalued US stocks that crushed earnings
Names like Sony and GSK are still cheap despite impressive earnings beats for Q2 2024.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,420.90 | 57.90 | -0.68% |
| CAC 40 | 8,047.92 | 151.79 | -1.85% |
| DAX 40 | 22,326.81 | 820.21 | -3.54% |
| Dow JONES (US) | 42,520.99 | 670.25 | -1.55% |
| FTSE 100 | 8,759.00 | 112.31 | -1.27% |
| HKSE | 22,941.77 | 64.50 | -0.28% |
| NASDAQ | 18,285.16 | 65.03 | -0.35% |
| Nikkei 225 | 37,331.18 | 454.29 | -1.20% |
| NZX 50 Index | 12,414.83 | 54.88 | -0.44% |
| S&P 500 | 5,778.15 | 71.57 | -1.22% |
| S&P/ASX 200 | 8,198.10 | 47.60 | -0.58% |
| SSE Composite Index | 3,324.21 | 7.28 | 0.22% |